SEC Contract Filing

Filing Date: 2021-03-04

Document Content:
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>4
<FILENAME>sdgr-ex1037_103.htm
<DESCRIPTION>EX-10.37
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
sdgr-ex1037_103.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL<font style="font-weight:bold;font-style:italic;"> Execution Version</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk39070372"></a>Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Triple asterisks denote omissions.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 10.37</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="margin-top:0pt;text-align:center;margin-bottom:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref53672148"></a><a name="_Ref53672148"></a>COLLABORATION AND LICENSE AGREEMENT</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">This Collaboration and License Agreement<font style="font-weight:normal;font-variant: normal;"> (this &#8220;</font><font style="font-variant: normal;">Agreement</font><font style="font-weight:normal;font-variant: normal;">&#8221;) is made and entered into as of November&#160;22, 2020 (the &#8220;</font><font style="font-variant: normal;">Effective Date</font><font style="font-weight:normal;font-variant: normal;">&#8221;) by and between </font>Schr&#246;dinger, Inc.<font style="font-weight:normal;font-variant: normal;">, a corporation organized under the laws of the State of Delaware, having its principal place of business at 120 West 45th Street, 17th Floor, New York, New York, 10036 (&#8220;</font><font style="font-variant: normal;">Schr&#246;dinger</font><font style="font-weight:normal;font-variant: normal;">&#8221;), and </font>Bristol-Myers Squibb Company<font style="font-weight:normal;font-variant: normal;">, a Delaware corporation headquartered at 430 East 29th Street, 14th Floor, New York, New York, USA 10016 (&#8220;</font><font style="font-variant: normal;">BMS</font><font style="font-weight:normal;font-variant: normal;">&#8221;). Schr&#246;dinger and BMS are sometimes referred to herein individually as a &#8220;</font><font style="font-variant: normal;">Party</font><font style="font-weight:normal;font-variant: normal;">&#8221; and collectively as the &#8220;</font><font style="font-variant: normal;">Parties</font><font style="font-weight:normal;font-variant: normal;">&#8221;. </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Whereas<font style="font-weight:normal;">, BMS is a biopharmaceutical company engaged in the research, development, manufacture and commercialization of human therapeutic products.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Whereas<font style="font-weight:normal;">, Schr&#246;dinger is a software and drug discovery company that has technology and expertise relating to the discovery and development of compounds directed to certain targets using its proprietary computational platform technology and drug discovery capabilities. </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Whereas<font style="font-weight:normal;">, Schr&#246;dinger and BMS desire to collaborate in the performance of a Research Program for the purpose of discovery and preclinical development of Licensed Collaboration Compounds for the Designated Targets suitable for development for human therapeutic uses, with the objective of identifying one or more Licensed Collaboration Compounds or Licensed Collaboration Products for the Designated Targets for BMS to advance into human clinical trials,